Fiche du document
24 février 2021
- doi: 10.53738/REVMED.2021.17.727.0383
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2021.17.727.0383
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33625803
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_83627E067A3D9
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Mots-clés
Drug-Related Side Effects and Adverse Reactions; Humans; Kidney; Kidney Transplantation; VasculitisSujets proches
Vasculitides Blood-vessels--Inflammation AngiitisCiter ce document
M. Halfon et al., « Complément et rein [Complement system and kidney] », Serveur académique Lausannois, ID : 10.53738/REVMED.2021.17.727.0383
Métriques
Partage / Export
Résumé
In the last few years, there has been a growing interest in the study of complement, fueleld mainly by the design of complement modulators, especially the C5-blocker eculizumab. The latter has significantly improved the prognosis of some nephropathies, such as the atypical hemolytic uremic syndrome. This breakthrough is a perfect example of fundamental translational research leading to clinical applications for patients. Currently, new molecules are being developed and some of them have already demonstrated clinical efficacy, such as avacopan (C5aR blocker) in ANCA vasculitis. As for kidney transplantation, complement modulators may lead to a new perspective in the treatment of some complications, such as humoral rejection. However, complement modulators carry the side effects, especially the infectious, and high costs.